Telisotuzumab vedotin for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Institutul Oncologic Prof Dr I Chiricuta /ID# 206320, Cluj Napoca, RomaniaNon-Small Cell Lung CancerTelisotuzumab vedotin - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is designed to find what population of Non-Small Cell Lung Cancer patients will respond best to the telisotuzumab vedotin therapy, and then to expand that group to further evaluate efficacy.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 8 Secondary · Reporting Duration: Up to approximately 3 years

Year 3
Disease Control Rate (DCR)
Disease Control Rate (DCR) (Stage 1 and Stage 2)
Duration of Response (DoR)
Duration of Response (DoR) (Stage 1 and Stage 2)
Number of Participants with Adverse Events (Alternate dose cohort)
Overall Response Rate (ORR)
Overall Response Rate (ORR) (Stage 1 and Stage 2)
Overall Survival (OS)
Overall Survival (OS) (Stage 1 and Stage 2)
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) (Stage 1 and Stage 2)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Telisotuzumab vedotin
1 of 1

Experimental Treatment

275 Total Participants · 1 Treatment Group

Primary Treatment: Telisotuzumab vedotin · No Placebo Group · Phase 2

Telisotuzumab vedotin
Experimental Group · 1 Intervention: Telisotuzumab vedotin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 3 years

Who is running the clinical trial?

AbbVieLead Sponsor
852 Previous Clinical Trials
473,376 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
313 Previous Clinical Trials
120,759 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What is the number of hospitals participating in this experiment?

"This clinical trial is enrolling participants at Icri, Highlands Oncology Group, The Ottawa Hospital and 55 other medical centres. Specifically, the Icri site has an ID of 227835 in Whittier, California; the Highlands Oncology Group's location has an ID number of 215600 located in Springdale Arkansas; and finally, The Ottawa Hospital's enrolment hub holds a unique identifier of 205579 situated in Ontario." - Anonymous Online Contributor

Unverified Answer

Is this experiment the inaugural endeavor of its type?

"Telisotuzumab vedotin has been investigated since its inception in 2014, sponsored by AbbVie. Following successful Phase 1 trials involving 260 participants, 3 more studies have commenced across 284 locations and 38 nations." - Anonymous Online Contributor

Unverified Answer

What can be said about the potential hazards of Telisotuzumab vedotin?

"The safety of Telisotuzumab vedotin was rated a 2, as evidence from the Phase 2 trial suggests that there is some level of safety but no data regarding efficacy." - Anonymous Online Contributor

Unverified Answer

How many individuals have enrolled in this investigation thus far?

"In order to conduct the study, AbbVie is seeking 270 participants that meet all inclusion criteria. The medical trial will be administered from Icri /Id# 227835 in Whittier, California and Highlands Oncology Group /ID# 215600 in Springdale, Arkansas." - Anonymous Online Contributor

Unverified Answer

What further research has been undertaken regarding Telisotuzumab vedotin?

"Presently, 3 clinical trials are actively studying Telisotuzumab vedotin's effects with one study in its third phase. Matsusaka-shi, Mie is the primary site of research; however, there are 587 other locations across the world conducting studies on this medication." - Anonymous Online Contributor

Unverified Answer

What is the main aim of this trial?

"This clinical trial, monitored for up to 3 years, aims to assess Overall Response Rate (ORR) and Disease Control Rate (DCR). Secondary measures include Duration of Response (DoR), which is the time from initial response until radiographic progression or death from any cause. Additionally, DCR will be calculated as a percentage of participants with best overall response out of confirmed CR, PR or stable disease lasting 12 weeks following enrolment according to RECIST v1.1 standards." - Anonymous Online Contributor

Unverified Answer

Is this medical experiment currently accepting participants?

"Affirmative. According to the information published on, this experiment begun recruiting participants on October 10th 2018 and its latest update was November 24th 2022. The study is in need of 270 patients across 55 distinct sites." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.